These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1032 related articles for article (PubMed ID: 23727931)

  • 1. A functional CFTR assay using primary cystic fibrosis intestinal organoids.
    Dekkers JF; Wiegerinck CL; de Jonge HR; Bronsveld I; Janssens HM; de Winter-de Groot KM; Brandsma AM; de Jong NW; Bijvelds MJ; Scholte BJ; Nieuwenhuis EE; van den Brink S; Clevers H; van der Ent CK; Middendorp S; Beekman JM
    Nat Med; 2013 Jul; 19(7):939-45. PubMed ID: 23727931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal organoids to model cystic fibrosis.
    van Mourik P; Beekman JM; van der Ent CK
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023844
    [No Abstract]   [Full Text] [Related]  

  • 3. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.
    Boj SF; Vonk AM; Statia M; Su J; Vries RR; Beekman JM; Clevers H
    J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations.
    de Winter-de Groot KM; Berkers G; Marck-van der Wilt REP; van der Meer R; Vonk A; Dekkers JF; Geerdink M; Michel S; Kruisselbrink E; Vries R; Clevers H; Vleggaar FP; Elias SG; Heijerman HGM; van der Ent CK; Beekman JM
    J Cyst Fibros; 2020 Jul; 19(4):614-619. PubMed ID: 31735562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect.
    Fidler MC; Buckley A; Sullivan JC; Statia M; Boj SF; Vries RGJ; Munck A; Higgins M; Moretto Zita M; Negulescu P; van Goor F; De Boeck K
    Clin Transl Sci; 2021 Mar; 14(2):656-663. PubMed ID: 33278322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.
    Vijftigschild LA; Berkers G; Dekkers JF; Zomer-van Ommen DD; Matthes E; Kruisselbrink E; Vonk A; Hensen CE; Heida-Michel S; Geerdink M; Janssens HM; van de Graaf EA; Bronsveld I; de Winter-de Groot KM; Majoor CJ; Heijerman HG; de Jonge HR; Hanrahan JW; van der Ent CK; Beekman JM
    Eur Respir J; 2016 Sep; 48(3):768-79. PubMed ID: 27471203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
    Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
    J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
    Dekkers JF; Berkers G; Kruisselbrink E; Vonk A; de Jonge HR; Janssens HM; Bronsveld I; van de Graaf EA; Nieuwenhuis EE; Houwen RH; Vleggaar FP; Escher JC; de Rijke YB; Majoor CJ; Heijerman HG; de Winter-de Groot KM; Clevers H; van der Ent CK; Beekman JM
    Sci Transl Med; 2016 Jun; 8(344):344ra84. PubMed ID: 27334259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant.
    Kondratyeva E; Bukharova T; Efremova A; Melyanovskaya Y; Bulatenko N; Davydenko K; Filatova A; Skoblov M; Krasovsky S; Petrova N; Polyakov A; Adyan T; Amelina E; Shadrina V; Zhekaite E; Zodbinova A; Chernyak A; Zinchenko R; Kutsev S; Goldshtein D
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.
    de Poel E; Spelier S; Suen SWF; Kruisselbrink E; Graeber SY; Mall MA; Weersink EJM; van der Eerden MM; Koppelman GH; van der Ent CK; Beekman JM
    J Cyst Fibros; 2022 Mar; 21(2):246-253. PubMed ID: 34666947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.
    Ramalho AS; Fürstová E; Vonk AM; Ferrante M; Verfaillie C; Dupont L; Boon M; Proesmans M; Beekman JM; Sarouk I; Vazquez Cordero C; Vermeulen F; De Boeck K;
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32747394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R560S: A class II CFTR mutation that is not rescued by current modulators.
    Awatade NT; Ramalho S; Silva IAL; Felício V; Botelho HM; de Poel E; Vonk A; Beekman JM; Farinha CM; Amaral MD
    J Cyst Fibros; 2019 Mar; 18(2):182-189. PubMed ID: 30030066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity.
    Zomer-van Ommen DD; de Poel E; Kruisselbrink E; Oppelaar H; Vonk AM; Janssens HM; van der Ent CK; Hagemeijer MC; Beekman JM
    J Cyst Fibros; 2018 May; 17(3):316-324. PubMed ID: 29544685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis of F508del CFTR in native human colon.
    van Barneveld A; Stanke F; Tamm S; Siebert B; Brandes G; Derichs N; Ballmann M; Junge S; Tümmler B
    Biochim Biophys Acta; 2010 Nov; 1802(11):1062-9. PubMed ID: 20696241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.
    de Poel E; Spelier S; Hagemeijer MC; van Mourik P; Suen SWF; Vonk AM; Brunsveld JE; Ithakisiou GN; Kruisselbrink E; Oppelaar H; Berkers G; de Winter de Groot KM; Heida-Michel S; Jans SR; van Panhuis H; Bakker M; van der Meer R; Roukema J; Dompeling E; Weersink EJM; Koppelman GH; Blaazer AR; Muijlwijk-Koezen JE; van der Ent CK; Beekman JM
    J Cyst Fibros; 2023 May; 22(3):548-559. PubMed ID: 37147251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis.
    Liu Z; Anderson JD; Deng L; Mackay S; Bailey J; Kersh L; Rowe SM; Guimbellot JS
    Genes (Basel); 2020 May; 11(6):. PubMed ID: 32485957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue of epithelial HCO3- secretion in murine intestine by apical membrane expression of the cystic fibrosis transmembrane conductance regulator mutant F508del.
    Xiao F; Li J; Singh AK; Riederer B; Wang J; Sultan A; Park H; Lee MG; Lamprecht G; Scholte BJ; De Jonge HR; Seidler U
    J Physiol; 2012 Nov; 590(21):5317-34. PubMed ID: 22802588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitors.
    Wilke M; Bot A; Jorna H; Scholte BJ; de Jonge HR
    PLoS One; 2012; 7(12):e52070. PubMed ID: 23284872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast.
    Latorre RV; Calicchia M; Bigliardi M; Conti J; Kleinfelder K; Melotti P; Sorio C
    Respir Investig; 2024 May; 62(3):455-461. PubMed ID: 38547757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.